top of page


Available as PDF, Word or Pages

BioSenic appoints Yves Sagot as Independent Director

Mont-Saint-Guibert, Belgium, January 27, 2023 – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today announces the appointment of Yves Sagot as a Member of the Board and Independent Director. 


BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes(TM) for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients

Sunnyvale, California, US and Mulhouse, France, February 1, 2023 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CellProthera, a private developer of cell-based therapies to repair ischemic tissues, today announce an amendment to their Clinical Research Supply and Support Agreement. 


The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy

Leriglitazone was well tolerated, and significant benefit was shown through clinically meaningful myelopathy endpoints and reduced progression of cerebral lesions


BioSenic appoints Dr Carole Nicco as Chief Scientific Officer

Dr Nicco will oversee the development of pipeline across BioSenic’s cell therapy and autoimmune disease platform and will be responsible for R&D programs


Immutep achieves 50 percent enrollment milestone in randomised Phase IIb TACTI-003 trial for first-line head and neck cancer 

Sydney, Australia, January 4th 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP)("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it has enrolled and randomised over 50 percent of the planned 154 patients in the TACTI-003 Phase IIb trial.


bottom of page